Renal replacement therapy in multiple myeloma and systemic amyloidosis.
Renal failure frequently complicates both multiple myeloma and systemic amyloidosis. Renal replacement therapy (RRT) may be poorly tolerated and its role in such patients is not clearly defined. Of fifty patients (26 males and 24 females) referred to a single centre because of renal failure associated with multiple myeloma or systemic amyloidosis 37 progressed to end-stage renal failure and 30 of these patients received RRT. Nine patients have been treated by CAPD, 13 by haemodialysis, and 8 patients have required both forms of dialysis. Overall one year and two year survival rates were 66% and 57% respectively. The median duration on RRT was 7.5 months (range 1-96 months) with a 51% one year, and a 46% two year survival rate. Of 7 patients with amyloidosis who underwent renal transplantation, 3 died within 6 months of transplantation. Undiagnosed cardiac involvement contributed to this early mortality. We conclude that renal replacement therapy is appropriate for some patients with multiple myeloma and systemic amyloidosis who develop endstage renal failure. Careful assessment and selection of patients is necessary prior to renal transplantation.
Brown
J H
JH
Mary G. McGeown Regional Nephrology Unit, Belfast City Hospital, N. Ireland.
Maxwell
A P
AP
Bruce
I
I
Murphy
B G
BG
Doherty
C C
CC
D000293:Adolescent; D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000150:complications*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000401:mortality / Q000628:therapy*; D016030:Kidney Transplantation; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011239:Prednisolone / Q000627:therapeutic use; D006435:Renal Dialysis; D012189:Retrospective Studies; D015996:Survival Rate
D011239:Prednisolone; D008558:Melphalan